We found that only NBQX had an effect on acute seizure development, resulting in a significantly higher number of mice experiencing seizures, an increase in the number of seizures per mouse, a greater cumulative seizure score per mouse and a significantly higher mortality rate …

DNQX is known to block the effect of agonists by competing for the same site on the receptor. When applied to rat hippocampal neurons in culture, DNQX produces a dose-dependent neurotoxicity, which seems to operate through a mechanism independent of …

NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity.

NBQX is a selective and competitive AMPA and kainate receptor antagonist (IC 50 = 0.15 μM and 4.8 μM, respectively). NBQX blocks the antidepressant effects of 8-Hydroxy-DPAT hydrobromide (Cat. No. 0529), decreases mTOR and BDNF levels.

2016年6月1日 · NBQX is a highly selective competitive antagonist of AMPA/KA glutamate receptors. NBQX had an effect on acute seizure development in the virus-induced seizure model. NBQX treatment resulted in a greater seizure burden, both incidence and severity. NBQX, a potent anticonvulsant, has the opposite effect on virus-induced seizures.

NBQX (2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline) is an analogue of the quinoxalinedione antagonists to the non-NMDA glutamate receptor. NBQX is a potent and selective inhibitor of binding to the quisqualate subtype of the glutamate receptor, with no activity at the NMDA and glycine site 3 .

1995年6月19日 · NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo (F)quinoxaline), a selective antagonist of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptors, at an anticonvulsant dose of 40 mg/kg (i.p.), was shown in vivo to have no effects on either the field potentials in the piriform cortex or those in the dentate gyrus of the hippocampus.